$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Biocon's Pebrilzo, a Perjeta Biosimilar

The Food and Drug Administration has approved Pebrilzo (pertuzumab-qcay), Biocon's biosimilar copy of Roche's Perjeta for HER2-positive breast cancer, the company announced on Monday, November 16. It's Biocon's fifth FDA-approved oncology biosimilar in the United States, but a patent settlement with Genentech sets the earliest licensed U.S. launch for the third quarter of 2028.

Pertuzumab bound to the HER2 receptor, the interaction Pebrilzo is built to reproduce (archive). Illustration: Takuma-sa, CC0, via Wikimedia Commons.
Summary

The approval is real and the wait is real. Pebrilzo cleared the FDA on the strength of similarity data, and then a settlement clock, not a regulatory one, holds it off the U.S. market for almost two more years.

Tap a passage. React to the part that matters.

The Food and Drug Administration has approved Pebrilzo (pertuzumab-qcay), Biocon Limited announced on Monday, November 16. Pebrilzo is a biosimilar to Perjeta (pertuzumab), Roche's HER2-targeted antibody for breast cancer, and it's the fifth oncology biosimilar Biocon has won approval for in the United States. The approval covers HER2-positive metastatic breast cancer, given with trastuzumab and docetaxel to patients who haven't had prior anti-HER2 therapy or chemotherapy for metastatic disease, and early-stage HER2-positive disease in neoadjuvant and adjuvant settings with trastuzumab and chemotherapy.

A biosimilar isn't a generic in the pill sense. It's a close copy of a medicine made from living cells, and the FDA clears it on a totality of evidence rather than a fresh round of large efficacy trials. Biocon says its package combined structural and functional analytical characterization, analytical similarity testing and comparative clinical pharmacokinetic data, and found no clinically meaningful differences from Perjeta in quality, safety, efficacy or immunogenicity.

Pertuzumab works by blocking HER2, a receptor that some breast cancers overproduce and use to drive their growth. It binds a different part of the receptor than trastuzumab does, which is why the two are paired. Biocon puts the U.S. context at roughly 320,000 women expected to be diagnosed with breast cancer in 2026. HER2-positive disease is the aggressive subset both drugs are aimed at.

Biocon is built for exactly this kind of copy work. The company is headquartered in Bengaluru, India, and its U.S. business is biosimilars: complex medicines reproduced closely enough that regulators will let them substitute for the originals. Each approval widens the catalog it can sell to American hospitals and insurers, and pertuzumab is a standard component of HER2-positive treatment regimens, which makes it a steadier product than a niche therapy with a handful of patients.

Approval and availability are two different dates here, and the gap is the story's hard edge. Biocon has signed a global settlement and license agreement with Genentech, the Roche unit that sells Perjeta, and that agreement sets the earliest licensed U.S. commercial launch for Pebrilzo in the third quarter of calendar 2028. The FDA has done its part. A patent settlement decides when a single vial can be sold.

The market read the approval the way the calendar says to. Biocon's shares rose about 0.9 percent in Mumbai trading on Monday, a move that prices the regulatory win without pricing any near-term American revenue, because there isn't any to price until the 2028 launch window opens. The same announcement carried the company's recent results, which showed a sharp drop in quarterly profit, and the stock still went up on the approval.

Pebrilzo joins Ogivri, Jobevne, Fulphila and Aukelso in Biocon's U.S. oncology biosimilar portfolio. Europe is moving on a parallel track: in September 2026 the European Medicines Agency's Committee for Medicinal Products for Human Use gave a positive opinion recommending marketing authorization for the same pertuzumab biosimilar under the Pebrilzo name, a recommendation that precedes a final European decision.

"The U.S. FDA approval of Pebrilzo, our biosimilar pertuzumab, marks another significant milestone in Biocon's journey to expand access to high-quality biosimilars," Shreehas Tambe, the company's chief executive and managing director, said in the announcement. The access argument is the whole commercial case for a biosimilar. It just doesn't start in the United States until 2028.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.